PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number	10/567,630-Conf. #2853
Filing Date	February 8, 2006
First Named Inventor	Kari Alitalo
Art Unit	1634
Examiner Name	Kapushoc
Attorney Docket Number	28113/39467A

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1*	US-4,946,778	08-07-1990	Ladner et al.	
	A2*	US-5,093,246	03-03-1992	Cech et al.	
	A3*	US-5,116,742	05-26-1992	Cech et al.	
	A4*	US-5,225,337	07-06-1993	Robertson et al.	
	A5*	US-5,254,678	10-19-1993	Haseloff et al.	
	A6*	US-5,939,598	08-17-1999	Kucherlapati et al.	
	A7*	US-2003/087807	05-08-2003	Greenspan R. J.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	B1	WO 90/07641	07-12-1990	Sundstrand Corporation		
	B2	WO 93/23569	11-25-1993	Ribozyme Pharmaceuticals, Inc.		
	B3	WO 94/02602	02-03-1994	Cell Genesys, Inc.		
	B4	WO 96/33735	10-31-1996	Cell Genesys, Inc.		
	B5	WO 96/34096	10-31-1996	Cell Genesys, Inc.		
	B6	WO 00/32765	06-08-2000	Immusol, Inc.		
	B7	WO 03/27285	04-03-2003	Bionomics Ltd.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	C1	Artavanis-Tsakonas, Notch Signaling: Cell fate control and signal integration in development. *Science*, Vol. 284, pp.770-776 (1999).	
	C2	Bach et al., Stem cells: The intestinal stem cell as paradigm. *Carcinogenesis*, Vol. 21, pp.469-476 (2000).	
	C3	Bange et al., Cancer progression and tumor cell motility are associated with the FGFR4 Arg388 allele. *Cancer Res.*, Vol. 62, pp.840-847 (2002).	
	C4	Brummelkamp et al., A system for stable expression of short interfering RNAs in mammalian cells. *Science*, Vol. 296, pp.550-553 (2002).	
	C5	Cavallaro et al., N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signaling. *Nat. Cell Biol.*, Vol. 3, pp.650-657 (2001).	
	C6	Chowrira et al., Extensive phosphorothioate substitution yields highly active and nuclease-resistant hairpin ribosymes. *Nucleic Acids Res.*, Vol. 20, pp.2835-2840 (1992).	
	C7	Cote et al., Generation of human monoclonal antibodies reactive with cellular antigens. *Proc.*	

Examiner Signature	/Stephen Kapushoc/	Date Considered	01/12/2010

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /STK/

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 4

Complete if Known	
Application Number	10/567,630-Conf. #2853
Filing Date	February 8, 2006
First Named Inventor	Kari Alitalo
Art Unit	~~1638~~ 1634
Examiner Name	~~Amy Bowman~~ Kapushoc
Attorney Docket Number	28113/39467A

		Natl. Acad. Sci. (USA), Vol. 80, pp.2026-2030 (1983).	
	C8	Daubendiek et al., Generation of catalytic RNAs by rolling transcription of synthetic DNA nanocircles. *Nat. Biotechnol.*, Vol. 15, No. 3, pp.273-277 (1997).	
	C9	Elbashir et al., RNA interference is mediated by 21- and 22-nucleotide RNAs. *Genes Dev.*, Vol. 15, pp.188-200 (2001).	
	C10	Elbashir et al., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature*, Vol. 411, pp.494-498 (2001).	
	C11	Fawell et al., Tat-mediated delivery of heterologous proteins into cells. *Proc. Natl. Acad. Sci. (USA)*, Vol. 91, pp.664-668 (1994).	
	C12	Ferkol et al., Regulation of the phosphoenolpyruvate carboxykinase/human factor IX gene introduced into the livers of adult rats by receptor-mediated gene transfer. *FASEB J.*, Vol. 7, pp.1081-1091 (1993).	
	C13	Fingl et al., Chapter 1: General Principles. "The Pharmacological Basis of Therapeutics," pp.1 (1975).	
	C14	Fire et al., Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. *Nature*, Vol. 391, pp.806-811 (1998).	
	C15	Fujimori et al., Regulation of lipocalin-type prostaglandin D synthase gene expression by Hes-1 through E-box and interleukin-1β via two NF-κB elements in rat leptomeningeal cells. *J. Biol. Chem.*, Vol. 278, pp.6018-6026 (2003).	
	C16	Giles et al., Caught up in a WNT storm: Wnt signaling in cancer. *Biochem. Biophys. Acta.*, Vol. 1653, pp.1-24 (2003).	
	C17	Gupta et al., Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. *Nat. Rev. Cancer*, Vol. 1, pp.11-21 (2001).	
	C18	Hong et al., Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. *Dev. Dyn.*, Vol. 225, pp.351-357 (2002).	
	C19	Hutvagner et al., A microRNA in a multiple-turnover RNAi enzyme complex. *Science*, Vol. 297, pp.2056-2060 (2002).	
	C20	Jensen et al., Control of endodermal endocrine development by Hes-1. *Nat. Genet.*, Vol. 24, pp.36-44 (2000).	
	C21	Jordan et al., Expression of functional CXCR4 chemokine receptors on human colonic epithelial cells. *J. Clin. Invest.*, Vol. 104, pp.1061-1069 (1999).	
	C22	Joutel et al., Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. *Nature*, Vol. 383, pp.707-710 (1996).	
	C23	Kaneda et al., Increased expression of DNA cointroduced with nuclear protein in adult rat liver. *Science*, Vol. 243, pp.375-378 (1989).	
	C24	Kato et al., Expression of hepatitis B virus surface antigen in adult rat liver. *J. Biol. Chem.*, Vol. 266, pp.3361-3364 (1991).	
	C25	Kawasaki et al., Hes1 is a target of microRNA-23 during retinoic-acid-induced neuronal differentiation of NT2 cells. *Nature*, Vol. 423, pp.838-842 (2003).	
	C26	Koizumi et al., Design of RNA enzyme distinguishing a single base mutation in RNA. *Nucleic Acid Res.*, Vol. 17, pp.7059-7071 (1989).	
	C27	Kurreck et al., Design of antisense oligonucleotides stabilized by locked nucleic acids. *Nucleic Acids Res.*, Vol. 30, pp.1911-1918 (2002).	
	C28	Ladner et al., dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. *Cancer Research*, Vol. 60, pp.3493-3503 (2000).	
	C29	Lee et al., Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. *Nat. Biotechnol.*, Vol. 20, pp.500-505 (2002).	

Examiner Signature	/Stephen Kapushoc/	Date Considered	01/12/2010

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /STK/

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 4

Complete if Known	
Application Number	10/567,630-Conf. #2853
Filing Date	February 8, 2006
First Named Inventor	Kari Alitalo
Art Unit	~~1635~~ 1634
Examiner Name	~~Amy Bowman~~ Kapushoc
Attorney Docket Number	28113/39467A

	C30	Li et al., Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. *Nature Genet.*, Vol. 16, pp.243-251 (1997).	
	C31	Lima et al., Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. *J. Biol. Chem.*, Vol. 272, pp.626-638 (1997).	
	C32	Long et al., Self-cleaving catalytic RNA. *FASEB J.*, Vol. 7, pp.25-30 (1993).	
	C33	Martinez et al., Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. *Cell,* Vol. 110, pp.563-574 (2002).	
	C34	Morrison et al., Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. *Proc. Natl. Acad. Sci. (USA),* Vol. 81, pp.6851-6855 (1984).	
	C35	Nagahara et al., Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. *Nature Medicine,* Vol. 4, pp.1449-1452 (1998).	
	C36	Nicolau et al., Liposomes as carriers for in vivo gene transfer and expression. *Methods Enzymol.*, Vol. 149, pp.157-176 (1987).	
	C37	Ojwang et al., Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. *Proc. Natl. Acad. Sci. (USA)*, Vol. 89, pp.10802-10806 (1992).	
	C38	Palmer et al., Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. *J. Cell Biol.*, Vol. 154, pp.369-387 (2001).	
	C39	Perales et al., Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. *Proc. Natl. Acad. Sci. (USA)*, Vol. 91, pp.4086-4090 (1994).	
	C40	Perrotta et al., Cleavage of oligoribonucleotides by a ribozyme derived from the hepatitis delta virus RNA sequence. *Biochem*, Vol. 31, pp.16-17 (1992).	
	C41	Petrova et al., Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. *Embo J.*, Vol. 21, pp.4593-4599 (2002).	
	C42	Quaroni et al., p27(Kip1) is an inducer of intestinal epithelial cell differentiation. *Am. J. Physiol. Cell. Physiol.*, Vol. 279, pp.C1045-1057 (2000).	
	C43	Schwarze et al., In vivo protein transduction: delivery of a biologically active protein into the mouse. *Science*, Vol. 285, pp.1569-1572 (1999).	
	C44	Sosa-Pineda et al., Hepatocyte migration during liver development requires Prox1. *Nat. Genet.*, Vol. 25, pp.254-255 (2000).	
	C45	Symons, Small catalytic RNAs. *Ann. Rev. Biochem.*, Vol. 61, pp.641 (1992).	
	C46	Takeda et al., Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences. *Nature*, Vol. 314, pp.452-454 (1985).	
	C47	Tomita et al., Isolation and characterization of a highly malignant variant of the SW480 human colon cancer cell line. *Cancer Res.*, Vol. 52, pp.6840-6847 (1992).	
	C48	Tuschl, Expanding small RNA interference. *Nat. Biotechnol.*, Vol. 20, pp.446-448 (2002).	
	C49	Usman et al., Hammerhead ribozyme engineering. *Current Opin. Struct. Biol.*, Vol. 6, pp.527-533 (1996).	
	C50	van de Wetering et al., The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. *Cell*, Vol. 111, pp.241-250 (2002).	
	C51	White et al., Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. *Cancer Res.*, Vol. 62, pp.1669-1675 (2002).	
	C52	Wigle et al., Prox1 function is required for the development of the murine lymphatic	

Examiner Signature	/Stephen Kapushoc/	Date Considered	01/12/2010

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /STK/

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 4

Complete if Known	
Application Number	10/567,630-Conf. #2853
Filing Date	February 8, 2006
First Named Inventor	Kari Alitalo
Art Unit	~~xxx~~ 1634
Examiner Name	~~xxxxxxxxx~~ Kapushoc
Attorney Docket Number	28113/39467A

		system. *Cell*, Vol. 98, pp.769-778 (1999).	
	C53	Wigle et al., Prox1 function is crucial for mouse lens-fibre elongation. *Nat. Genet.*, Vol. 21, pp.318-33 (1999).	
	C54	Wigle et al. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. *EMBO J.* 21:1505-1513 (2002).	
	C55	Yamada et al., Fibroblast growth factor receptor (FGFR) 4 correlated with the malignancy of human astrocytomas. *Neurol Res.*, Vol. 24, pp.244-248 (2002).	
	C56	Yang et al., Targeted inactivation of the p21(WAF1/cip1) gene enhances Apc-initiated tumor formation and the tumor-promoting activity of a Western-style high-risk diet by altering cell maturation in the intestinal mucosal. *Cancer Res.*, Vol. 61, pp.565-569 (2001).	
	C57	Yang et al., Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. *Science*, Vol. 294, pp.2155-2158 (2001).	
	C58	Yu et al., RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. *Proc. Natl. Acad. Sci.* (USA), Vol. 99, pp.6047-6052 (2002).	
	C59	Zeng et al., Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. *Mol. Cell*, Vol. 9, pp.1327-1333 (2002).	
	C60	International Preliminary Report on Patentability, PCT/EP2004/008819, dated February 13, 2006.	

Examiner Signature	/Stephen Kapushoc/	Date Considered	01/12/2010

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /STK/